These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1998983)

  • 1. Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
    Wang AM; Elion GB; Friedman HS; Bodell WJ; Bigner DD; Schold SC
    Cancer Chemother Pharmacol; 1991; 27(4):278-84. PubMed ID: 1998983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
    Smith DC; Vick NA; Trump DL; Friedman HS; Friedman AH; Purvis J; Gauspari A; Schold SC
    Cancer Chemother Pharmacol; 1992; 30(4):272-6. PubMed ID: 1643694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
    Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
    Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
    Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
    Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
    Schold SC; Rawlings CE; Bigner SH; Bigner DD
    Neurosurgery; 1983 Jun; 12(6):672-7. PubMed ID: 6683794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
    Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
    Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
    Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
    Kyritsis AP; Yung WK; Jaeckle KA; Bruner J; Gleason MJ; Ictech SE; Flowers A; Levin VA
    Neurosurgery; 1996 Nov; 39(5):921-6. PubMed ID: 8905746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
    Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
    Slagel DE; Feola J; Houchens DP; Ovejera AA
    Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone.
    Gerson SL; Zborowska E; Norton K; Gordon NH; Willson JK
    Biochem Pharmacol; 1993 Jan; 45(2):483-91. PubMed ID: 8435098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
    Schold SC; Bigner DD
    Cancer Treat Rep; 1983 Sep; 67(9):811-9. PubMed ID: 6224556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
    Coggins CA; Elion GB; Houghton PJ; Hare CB; Keir S; Colvin OM; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1998; 41(6):485-90. PubMed ID: 9554593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential response to 1,3-bis (2-chloroethyl)-1-nitrosourea in drug-resistant and -sensitive 9L rat brain tumor cells pretreated with alpha-difluoromethylornithine and 6-thioguanine.
    Hunter KJ; Deen DF; Marton LJ
    Int J Cancer; 1989 Oct; 44(4):658-60. PubMed ID: 2507451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
    Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
    Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU.
    Levin VA; Stearns J; Byrd A; Finn A; Weinkam RJ
    J Pharmacol Exp Ther; 1979 Jan; 208(1):1-6. PubMed ID: 759602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
    Branle F; Lefranc F; Camby I; Jeuken J; Geurts-Moespot A; Sprenger S; Sweep F; Kiss R; Salmon I
    Cancer; 2002 Aug; 95(3):641-55. PubMed ID: 12209758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.
    Ali-Osman F; Giblin J; Berger M; Murphy MJ; Rosenblum ML
    Cancer Res; 1985 Sep; 45(9):4185-91. PubMed ID: 2411398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
    Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
    J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.